Friedrich K.
- Country
- Germany
- Department
- Universitätsklinikum Erlangen Augenklinik
Research Overview
- Phase 3 Evaluation of Ripasudil (K-321) Eye Drops on Visual Acuity Post-Descemetorhexis in Fuchs Endothelial Corneal Dystrophy Patients
- A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12 Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy
Data & Insights
Has run more than one trial at 13 of 17 partner sites.
Specializations
Ophthalmology Focus
This investigator specializes in treating Fuchs Endothelial Corneal Dystrophy (FECD), demonstrating particular expertise in corneal conditions and their management.
- Corneal Disorders
- Visual Acuity Assessment
- Endothelial Cell Research
The investigator's work encompasses innovative treatments for corneal dystrophies using advanced therapeutic approaches.
Surgical Expertise
Specialized experience in descemetorhexis procedures and cataract surgery, with particular focus on combined surgical interventions for corneal conditions.
- Corneal Surgery Techniques
- Combined Surgical Procedures
- Post-operative Care
Expertise extends to advanced surgical techniques for treating complex corneal disorders.
Therapeutic Development
Active involvement in evaluating new therapeutic approaches including ophthalmic solutions for corneal disorders, with emphasis on visual acuity improvement.
- Novel Eye Drop Therapies
- Visual Recovery Assessment
- Treatment Optimization
The investigator focuses on developing effective treatment protocols for corneal conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.